Fresenius SE KGaA Resultados de beneficios anteriores

Pasado controles de criterios 1/6

Los beneficios de Fresenius SE KGaA han disminuido a una tasa media anual de -14.5%, mientras que en la industria Healthcare los beneficios crecieron en un 4.4% anualmente. Los ingresos han ido disminuyendo a una tasa media de 1.4% al año. La rentabilidad financiera de Fresenius SE KGaA es de 1.2%, y sus márgenes netos son de 1.6%.

Información clave

-18.7%

Tasa de crecimiento de los beneficios

-18.9%

Tasa de crecimiento del BPA

Crecimiento de la industria Healthcare	15.7%
Tasa de crecimiento de los ingresos	-5.8%
Rentabilidad financiera	1.0%
Margen neto	1.4%
Próxima actualización de resultados	31 Jul 2024

Actualizaciones de resultados anteriores recientes

Recent updates

At €29.20, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

May 28

With Fresenius SE & Co. KGaA (ETR:FRE) It Looks Like You'll Get What You Pay For

May 02

Fresenius SE & Co. KGaA (ETR:FRE) Analysts Just Trimmed Their Revenue Forecasts By 34%

Nov 10

Fresenius SE KGaA (ETR:FRE) Is Reinvesting At Lower Rates Of Return

Oct 27

Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Sep 03

Some Investors May Be Worried About Fresenius SE KGaA's (ETR:FRE) Returns On Capital

Jul 25

We Think Fresenius SE KGaA (ETR:FRE) Is Taking Some Risk With Its Debt

Jun 19

At €25.59, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

Jun 01

Capital Allocation Trends At Fresenius SE KGaA (ETR:FRE) Aren't Ideal

Apr 18

Fresenius SE KGaA's (ETR:FRE) Soft Earnings Are Actually Better Than They Appear

Mar 13

These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Extensively

Mar 10

Are Investors Undervaluing Fresenius SE & Co. KGaA (ETR:FRE) By 38%?

Feb 23

Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Feb 08

The Returns On Capital At Fresenius SE KGaA (ETR:FRE) Don't Inspire Confidence

Jan 03

These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Extensively

Nov 28

Should You Investigate Fresenius SE & Co. KGaA (ETR:FRE) At €21.71?

Oct 23

The Returns On Capital At Fresenius SE KGaA (ETR:FRE) Don't Inspire Confidence

Oct 01

Is Fresenius SE KGaA (ETR:FRE) Using Too Much Debt?

Aug 07

Is It Time To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Jul 20

Fresenius SE KGaA (ETR:FRE) May Have Issues Allocating Its Capital

Jul 02

Fresenius SE KGaA (ETR:FRE) Is Increasing Its Dividend To €0.92

Apr 28

At €34.09, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

Apr 17

Fresenius SE KGaA (ETR:FRE) Is Paying Out A Larger Dividend Than Last Year

Apr 02

Fresenius SE KGaA (ETR:FRE) Could Be Struggling To Allocate Capital

Mar 27

Fresenius SE KGaA's (ETR:FRE) Upcoming Dividend Will Be Larger Than Last Year's

Feb 24

Is Now An Opportune Moment To Examine Fresenius SE & Co. KGaA (ETR:FRE)?

Jan 13

Here's Why Fresenius SE KGaA (ETR:FRE) Has A Meaningful Debt Burden

Dec 29

Fresenius SE KGaA (ETR:FRE) Could Be Struggling To Allocate Capital

Dec 14

At €41.20, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

Oct 15

Is Fresenius SE KGaA (ETR:FRE) A Risky Investment?

Sep 30

Fresenius SE KGaA (ETR:FRE) Is Reinvesting At Lower Rates Of Return

Sep 15

Is Now The Time To Look At Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Jul 17

Fresenius SE KGaA (ETR:FRE) Takes On Some Risk With Its Use Of Debt

Jul 01

Desglose de ingresos y gastos

Cómo gana y gasta dinero Fresenius SE KGaA. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

XTRA:FRE Ingresos, gastos y beneficios (EUR Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Mar 24	22,457	312	3,174	604
31 Dec 23	22,299	353	3,155	608
30 Sep 23	41,599	941	6,916	875
30 Jun 23	41,467	1,026	6,941	853
31 Mar 23	17,358	1,060	2,390	578
31 Dec 22	21,532	1,154	3,094	614
30 Sep 22	25,828	1,444	3,561	610
30 Jun 22	29,766	1,611	4,080	677
31 Mar 22	38,256	1,796	5,580	777
31 Dec 21	37,520	1,818	5,453	784
30 Sep 21	36,858	1,729	5,423	800
30 Jun 21	36,452	1,743	5,341	757
31 Mar 21	36,126	1,683	5,149	758
31 Dec 20	36,277	1,707	5,235	758
30 Sep 20	36,284	1,812	5,378	741
30 Jun 20	36,208	1,829	5,418	752
31 Mar 20	36,049	1,889	5,517	698
31 Dec 19	35,409	1,883	5,406	660
30 Sep 19	34,933	1,884	5,159	644
30 Jun 19	34,283	1,859	5,105	613
31 Mar 19	33,904	2,040	4,991	635
31 Dec 18	33,530	2,027	4,893	646
30 Sep 18	33,390	2,022	5,136	660
30 Jun 18	33,495	1,999	5,177	640
31 Mar 18	33,645	1,797	5,341	596
31 Dec 17	33,886	1,814	5,554	558
30 Sep 17	33,011	1,745	5,192	524
30 Jun 17	32,147	1,731	5,143	513
31 Mar 17	30,818	1,659	4,933	508
31 Dec 16	29,471	1,560	4,742	502
30 Sep 16	28,908	1,477	4,620	480
30 Jun 16	28,415	1,452	4,489	473
31 Mar 16	28,158	1,399	4,413	473
31 Dec 15	27,626	1,358	4,195	464
30 Sep 15	26,889	1,256	4,031	443
30 Jun 15	25,927	1,175	3,832	422
31 Mar 15	24,502	1,136	3,533	394
31 Dec 14	23,231	1,067	3,359	369
30 Sep 14	22,010	1,094	3,170	359
30 Jun 14	21,077	1,083	3,057	351
31 Mar 14	20,653	1,040	3,055	352
31 Dec 13	20,331	1,011	3,044	348
30 Sep 13	20,440	974	3,325	341
30 Jun 13	20,259	952	3,293	330

Ingresos de calidad: FRE tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio(1.6%) de FRE son inferiores a los del año pasado (5.4%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de FRE han disminuido en un 14.5% al año en los últimos 5 años.

Acelerando crecimiento: FRE ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.

Beneficios vs. Industria: FRE tuvo un crecimiento negativo de los beneficios (-69.4%) durante el año pasado, lo que dificulta la comparación con la media de la industria Healthcare (-7.5%).

Fresenius SE KGaA Resultados de beneficios anteriores

Pasado controles de criterios 1/6

Información clave

Actualizaciones de resultados anteriores recientes

First quarter 2024 earnings released: EPS: €0.49 (vs €0.61 in 1Q 2023)

Fresenius SE & Co. KGaA to Report Fiscal Year 2023 Final Results on Mar 14, 2024

Third quarter 2023 earnings released: €0.72 loss per share (vs €0.57 profit in 3Q 2022)

Fresenius SE & Co. KGaA to Report Q2, 2024 Results on Jul 31, 2024

Second quarter 2023 earnings: EPS misses analyst expectations

Fresenius SE & Co. KGaA to Report Q3, 2023 Results on Nov 02, 2023

Recent updates

At €29.20, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

First quarter 2024 earnings released: EPS: €0.49 (vs €0.61 in 1Q 2023)

PAI Mid-Market Fund SCSp. managed by PAI Partners agreed to acquire 67% stake in Vamed rehabilitation business from Fresenius SE & Co. KGaA (XTRA:FRE).

With Fresenius SE & Co. KGaA (ETR:FRE) It Looks Like You'll Get What You Pay For

Verme family with other shareholders completed the acquisition of additional 70% stake in Clinica Ricardo Palma S.A. from Fresenius SE & Co. KGaA (XTRA:FRE).

Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

New major risk - Financial position

Fresenius SE KGaA (ETR:FRE) Could Be At Risk Of Shrinking As A Company

Consensus EPS estimates fall by 11%

Why Fresenius SE & Co. KGaA (ETR:FRE) Could Be Worth Watching

IVIRMA Global SL and GED Iberian Private Equity, S.A., SGEIC completed the acquisition of EUVITRO S.L.U. from Fresenius SE & Co. KGaA (XTRA:FRE).

Consensus EPS estimates fall by 15%

Consensus EPS estimates fall by 15%

German Fresenius Reportedly Seeks to Sell Vamed Reha

Consensus EPS estimates fall by 20%

Consensus EPS estimates fall by 20%

A Look At The Fair Value Of Fresenius SE & Co. KGaA (ETR:FRE)

Fresenius SE & Co. KGaA's (ETR:FRE) Shares Not Telling The Full Story

Fresenius SE & Co. KGaA to Report Fiscal Year 2023 Final Results on Mar 14, 2024

Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

Consensus EPS estimates increase by 57%

Fresenius SE & Co. KGaA (ETR:FRE) Analysts Just Trimmed Their Revenue Forecasts By 34%

IVIRMA Global SL and GED Iberian Private Equity, S.A., SGEIC agreed to acquire EUVITRO S.L.U. from Fresenius SE & Co. KGaA (XTRA:FRE) for €500 million.

Third quarter 2023 earnings released: €0.72 loss per share (vs €0.57 profit in 3Q 2022)

Consensus revenue estimates decrease by 46%

Fresenius SE & Co. KGaA to Report Q2, 2024 Results on Jul 31, 2024

Fresenius SE KGaA (ETR:FRE) Is Reinvesting At Lower Rates Of Return

KKR in Talks to Buy Eugin from Fresenius

Fresenius Reportedly Plans to Offload Digital Subsidiary Curalie

Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Consensus EPS estimates fall by 14%

New major risk - Financial position

Second quarter 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates increase by 14%

Fresenius SE & Co. KGaA to Report Q3, 2023 Results on Nov 02, 2023

Some Investors May Be Worried About Fresenius SE KGaA's (ETR:FRE) Returns On Capital

We Think Fresenius SE KGaA (ETR:FRE) Is Taking Some Risk With Its Debt

At €25.59, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

Fresenius Se & Co. Kgaa Proposes Dividend for 2022

Upcoming dividend of €0.92 per share at 3.3% yield

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Fresenius SE & Co. KGaA to Report Q1, 2023 Results on May 09, 2023

Capital Allocation Trends At Fresenius SE KGaA (ETR:FRE) Aren't Ideal

Consensus EPS estimates fall by 17%

Fresenius SE KGaA's (ETR:FRE) Soft Earnings Are Actually Better Than They Appear

These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Extensively

Full year 2022 earnings: EPS misses analyst expectations

Are Investors Undervaluing Fresenius SE & Co. KGaA (ETR:FRE) By 38%?

Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

The Returns On Capital At Fresenius SE KGaA (ETR:FRE) Don't Inspire Confidence

Fresenius SE & Co. KGaA, Annual General Meeting, May 17, 2023

These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Extensively

QIC Reportedly Set to Clinch Healius Day Hospital Unit for $140 Million Plus

Third quarter 2022 earnings released: EPS: €0.57 (vs €0.74 in 3Q 2021)

Should You Investigate Fresenius SE & Co. KGaA (ETR:FRE) At €21.71?

Brookfield Reportedly Drops Out of Race to Buy Healius

The Returns On Capital At Fresenius SE KGaA (ETR:FRE) Don't Inspire Confidence

Fresenius SE Announces Chief Financial Officer Changes

Fresenius SE & Co. KGaA Announces Michael Sen as CEO on October 1, 2022 Succeeding Stephan Sturm

Is Fresenius SE KGaA (ETR:FRE) Using Too Much Debt?

Price target decreased to €40.39

Second quarter 2022 earnings: EPS misses analyst expectations

Healius Reportedly Launches Day Surgery Sale Process

Is It Time To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Fresenius Kabi Introduces Generic Iodixanol Contrast Media Agent

Fresenius SE KGaA (ETR:FRE) May Have Issues Allocating Its Capital

Upcoming dividend of €0.92 per share

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Fresenius SE KGaA (ETR:FRE) Is Increasing Its Dividend To €0.92